Generic placeholder image

Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)


ISSN (Print): 1871-5222
ISSN (Online): 1875-6115

Myostatin Inhibition and Cardiometabolic Disorders

Author(s): Powen Tu, Shalender Bhasin and Wen Guo

Volume 10, Issue 4, 2010

Page: [232 - 239] Pages: 8

DOI: 10.2174/187152210793663784

Price: $65


Age-associated loss of skeletal muscle mass and strength, termed sarcopenia, is a major public health concern. Individuals with sarcopenia and frailty have decreased physical function and are at increased risk of cardiovascular and metabolic disorders. Despite the remarkable gains in the human health span, cardiometabolic disorders remain the leading cause of mortality worldwide. Here, we discuss the potential therapeutic implications of promyogenic function promoting anabolic agents, particularly myostatin antagonists, in the prevention of a variety of age-related metabolic disorders.

Keywords: Myostatin, muscle hypertrophy, lipid metabolism, insulin resistance, atherogenesis, Cardiometabolic Disorders, sarcopenia, promyogenic, obesity, diabetes, hepatic steatosis, atherosclerotic heart disease, IGF-1, modulators, Ldlr, ACVRIIB, hypoadiposity, RER, sensitivity, glucose, glucagon, Akt, skeletal muscle, phosphoryation, TNF, leptin, cytokines, myokines, lipolytic, IL-6, Fgf-21, Fstl-1, RNAi, aging, SREBP-1, mRNA, VLDL, LDL, Smad2/3

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy